CT-059X

N/A

Report date: 2025/04/08 17:08:05

Base Information

Drug NameCT-059X
Drug Alias NameCT059XCT-059X
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionT lymphocyte replacementsAnti-BCMA
TargetsB-cell maturation protein
Therapy Area/IndicationsMultiple MyelomaLeukemia, Plasma Cell
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusClinical
Highest Status in ChinaClinical
Originator CompaniesCARsgen Therapeutics Holdings Ltd
China Registration ClassN/A

Develop Information

Active CompaniesCarsgen Therapeutics ltd
Inactive CompaniesN/A
Active IndicationsMultiple MyelomaLeukemia, Plasma Cell
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A